SALT LAKE CITY—Gilbert A. Fuller, a director at USANA Health Sciences Inc . (NYSE:USNA), reported a series of stock transactions according to a recent SEC filing. On November 4, Fuller sold 675 shares of USANA common stock at an average price of $37.71 per share, totaling approximately $25,457.
Prior to the sale, Fuller acquired 675 shares of common stock on November 2 through the exercise of restricted stock units. These units, which vest in increments, represent a right to receive shares of USANA common stock. Following these transactions, Fuller does not hold any shares directly.
USANA Health Sciences, headquartered in Salt Lake City, specializes in the development and manufacture of nutritional supplements and personal care products.
In other recent news, Usana Health Sciences Inc. has reported a challenging third quarter, with net sales falling below expectations. The company's CEO, Jim Brown, has attributed this downturn to a difficult operating environment, especially in China, where net sales decreased by 4% despite a 7% rise in active customer counts. In an effort to regain momentum, Usana has announced plans to increase promotional activities in the fourth quarter.
These recent developments have also led to the launch of new products such as the Celavive Resurfacing Serum and Whey Protein Isolate in North America. The company has expressed its commitment to product innovation and rebuilding trust with sales associates. In addition to this, Usana has revised its EPS guidance for Q4 to reflect the increased spending.
Analysts have noted that Usana's strategy includes increasing the frequency of new, high-quality product launches. The focus for 2025 will be primarily on expanding the nutritionals category, with additional beauty and wellness products. Despite the current challenges, Usana's leadership remains cautiously optimistic about the long-term potential of the Chinese market, encouraged by government stimulus measures.
InvestingPro Insights
While Gilbert A. Fuller's recent stock transactions provide insight into insider activity at USANA Health Sciences Inc. (NYSE:USNA), a broader look at the company's financial metrics offers additional context for investors.
According to InvestingPro data, USANA's market capitalization stands at $736.18 million, with a price-to-earnings (P/E) ratio of 13.57. This relatively low earnings multiple, highlighted as an InvestingPro Tip, suggests the stock may be undervalued compared to its earnings potential. The company's impressive gross profit margin of 80.86% for the last twelve months ending Q3 2024 underscores its efficiency in manufacturing and selling its nutritional supplements and personal care products.
Another InvestingPro Tip reveals that USANA holds more cash than debt on its balance sheet, indicating a strong financial position. This aligns with the company's ability to fund stock repurchases and potentially weather economic uncertainties.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips that could provide valuable insights into USANA's financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.